Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ORKA
ORUKA THERAPEUTICS, INC.
NASDAQ
$92.51
▲ UP 1.67% (1.52)

KEY STATISTICS

Market Cap$5.59 B
52w High$115.52
52w Low$14.67
Dividend Yield64.52%
FrequencySpecial
P/E-47.69
Volume585.34K
Shares Out.60.31M

COMPANY

LEADERSHIP

Lawrence Otto Klein
CHIEF EXECUTIVE
Lawrence Otto Klein

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 8, 1997
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
68

PRICE TARGET

Target High$200.00
Target Low$120.00
Target Median$151.00
Target Consensus$149.56

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2024-09-03Reverse1:12
2019-04-04Reverse1:18
2015-09-04Reverse1:7
2013-03-05Reverse1:6
2009-01-28Reverse1:20
2004-02-23Reverse1:3

PRICE

$92.51 ▲ UP 1.67% (+$1.52)
OVERLAYS
$90.00$91.50$93.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM92.51

About Oruka Therapeutics, Inc.

http://www.orukatx.com ↗

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

INDUSTRY

Biotechnology

A PRODUCT ORUKA THERAPEUTICS, INC. IS KNOWN FOR

ORKA-001
ORKA-001

ORKA-001 is a long-acting IL-23p19 antibody in Phase 2b, developed by Oruka Therapeutics, aiming for once-yearly dosing to improve convenience in treating plaque psoriasis.

COMPETITORS

COMPETITOR
ABBV COMPARE
AMGN COMPARE
JNJ COMPARE
LLY COMPARE
NVS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
145
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 1.7M
XBI
1.31% · 1.7M
IWM
0.15% · 1.3M
TCAF
0.36% · 343.3K
SCHA
0.10% · 241.1K
CGMM
0.49% · 180.7K
JSMD
0.71% · 83.0K
SBIO
3.06% · 81.4K
PTH
2.46% · 73.2K
FESM
0.10% · 68.7K
LABU
0.86% · 55.2K
USVM
0.25% · 47.7K
XRS2.F
0.15% · 45.4K
DFAS
0.02% · 42.3K
RSSL
0.15% · 24.1K
GSSC
0.09% · 10.7K
BBSC
0.13% · 10.2K
AFSM
0.38% · 5.3K
BBC
0.81% · 4.5K
RTWP.L
0.13% · 3.3K
MEDI
0.60% · 2.9K
BIB
0.18% · 2.2K
BKSE
0.21% · 2.1K
RFLR
0.17% · 1.8K
W311.DE
0.81% · 1.4K
BR
BRSM
0.28% · 848

INSTITUTIONAL OWNERSHIP

SHARES OWNED
71.24%
HOLDERS
283
TOP 12 OF 283 · RANKED BY POSITION SIZE
Fmr LLC
9.1M sh · $862.02M
Blackrock, Inc.
5.0M sh · $474.92M
Vr Adviser, LLC
4.1M sh · $79.77M
Fairmount Funds Management LLC
3.7M sh · $352.63M
Capital World Investors
3.4M sh · $323.73M
Rtw Investments, LP
3.1M sh · $298.74M
State Street Corp
2.7M sh · $254.38M
Viking Global Investors LP
2.7M sh · $130.8M
Deep Track Capital, LP
2.7M sh · $51.05M
Vanguard Group Inc
2.5M sh · $74.37M
Paradigm Biocapital Advisors LP
2.3M sh · $113.81M
Commodore Capital LP
1.8M sh · $53.14M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF OPERATING OFFICER
Sandler Laura Lee
Purchase · 5.0K shares
2026-09-01
★
OFFICER: CHIEF OPERATING OFFICER
Sandler Laura Lee
Sale · 1.0K shares
2026-09-01
★
OFFICER: CHIEF OPERATING OFFICER
Sandler Laura Lee
Sale · 4.0K shares
2026-09-01
★
OFFICER: CHIEF OPERATING OFFICER
Sandler Laura Lee
Sale · 5.0K shares
2026-09-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 2
OVERWEIGHT 1
9 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY BTIG BUY Guggenheim BUY Wedbush OUTPERFORM UBS BUY Barclays OVERWEIGHT Leerink Partners OUTPERFORM Stifel BUY

SECTORS PEERS

PEERPRICE
NRIX$25.86COMPARE
RAPP$46.67COMPARE
KOD$35.63COMPARE
URGN$43.88COMPARE
XNCR$26.61COMPARE
ANAB$56.46COMPARE
PHAT$9.28COMPARE
BBOT$9.03COMPARE